- Home
- KAVL vs TOVX Comparison
KAVL vs TOVX Comparison
Compare KAVL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- TOVX
- Stock Information
- Founded
- KAVL 1998
- TOVX 2001
- Country
- KAVL United States
- TOVX United States
- Employees
- KAVL N/A
- TOVX N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- TOVX Health Care
- Exchange
- KAVL Nasdaq
- TOVX Nasdaq
- Market Cap
- KAVL 5.6M
- TOVX 4.5M
- IPO Year
- KAVL N/A
- TOVX 2006
- Fundamental
- Price
- KAVL $0.48
- TOVX $0.50
- Analyst Decision
- KAVL
- TOVX Hold
- Analyst Count
- KAVL 0
- TOVX 1
- Target Price
- KAVL N/A
- TOVX N/A
- AVG Volume (30 Days)
- KAVL 1.2M
- TOVX 170.2K
- Earning Date
- KAVL 09-19-2025
- TOVX 08-12-2025
- Dividend Yield
- KAVL N/A
- TOVX N/A
- EPS Growth
- KAVL N/A
- TOVX N/A
- EPS
- KAVL N/A
- TOVX N/A
- Revenue
- KAVL $1,698,426.00
- TOVX N/A
- Revenue This Year
- KAVL N/A
- TOVX N/A
- Revenue Next Year
- KAVL N/A
- TOVX N/A
- P/E Ratio
- KAVL N/A
- TOVX N/A
- Revenue Growth
- KAVL N/A
- TOVX N/A
- 52 Week Low
- KAVL $0.45
- TOVX $0.40
- 52 Week High
- KAVL $1.95
- TOVX $7.25
- Technical
- Relative Strength Index (RSI)
- KAVL 44.22
- TOVX 52.75
- Support Level
- KAVL $0.45
- TOVX $0.45
- Resistance Level
- KAVL $0.51
- TOVX $0.52
- Average True Range (ATR)
- KAVL 0.07
- TOVX 0.03
- MACD
- KAVL -0.00
- TOVX 0.01
- Stochastic Oscillator
- KAVL 5.83
- TOVX 77.78
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.